Great summary iconoclast. 

"Sixth, I think people are way underappreciating the 18 to 21% RRR.  This is in a very sick patient group, so every RRR percentage is a lot more valuable (in $ terms) than in a healthier population.  I would like to know the RRR for statins and SGLT2.  For Amarin's Vasepa, it was 25%. "

Good point here. No trial....I repeat no trial, has been shown to reduce MACE in recent ACS diabetics. EXAMINE, ELIXA, ALE-CARDIO all failed. These trials clearly failed. BETonMACE, on the other hand, barely failed. Apabetalone has big potential still and failed not due to lack of efficacy but due to being underpowered. 

No idea about statin RRR since LDL-C lowering is such basic standard of care now. Everything nowadays is on top of statin. SGLT2 inhibitors canagliflozin in CANVAS and empagliflozin in EMPA-REG OUTCOME achieved 14% RRR. But these were not in recent ACS diabetics.

Huge potential for apabetalone. BETonMACE great proof of concept.

BearDownAZ